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ABSTRACT 
Background and Objectives: Hypertension develops as a result of cardiac hypertrophy and fibrosis or as a result 
of exchange of the extracellular matrix. In particular, matrix metalloproteinase (MMP)-3 is a major enzyme 
involved in the reconstruction of the arterial intima through activation of other MMPs. We analyzed MMP-3 
genotypes in hypertensive and normotensive adolescents and sought to determine if a particular genotype is a 
predictor of cardiovascular complications. Subjects and Methods: Forty-four hypertensive adolescents and 59 
healthy adolescents were included in this study. Serum aldosterone, renin, insulin, angiotensin converting enzyme 
(ACE), insulin, homocysteine, vitamin B12, folate, MMP-1, MMP-2, MMP-3, MMP-9, tissue inhibitors of matrix 
metalloproteinases (TIMP)-1, and TIMP-2 were measured. MMP-3 genotypes were analyzed using a polymerase 
chain reaction (PCR) primer. The carotid intima media thickness (IMT), diameter, and brachial ankle pulse wave 
velocity  (baPWV) were evaluated using ultrasound. Results: In hypertensive adolescents, blood pressure, 
anthropometric data, carotid IMT, baPWV, serum pro-MMP-1, MMP-2, MMP-9, TIMP-1, and TIMP-2 were no 
different between the 6A/6A group and the 5A/6A group. Serum MMP-9 was higher in the 5A/6A group than 
in the control group. Aldosterone, insulin, and homocysteine were higher in the 6A/6A group than in the 
control group, and vitamin B12 and folate were lower in the 6A/6A group than in the control group. Conclusion: 
In conclusion, serum MMP-3 levels were not significantly different in different MMP-3 genotypes in hypertensive 
adolescents. However, few patients were included in this study. Further investigation is necessary to clarify the 
relationship between MMP-3 genotype and cardiovascular risk. (Korean Circ J 2009;39:328-334) 
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Introduction 
 
Hypertension is influenced by the interaction of var-
ious environmental and genetic factors. The genetic in-
fluence is speculated to be responsible for 30-40% of 
the blood pressure variation.
1) Although much progress 
has been made during the past 20 years with regard to 
our knowledge of the genetic background of essential 
hypertension, studies concerning the candidate genes in 
various populations have produced inconsistent and 
often unclear results.
2)3) 
Hypertension is associated with cardiovascular remod-
eling, including myocardial hypertrophy and fibrosis, 
which have been shown to be characterized by an in-
crease in extracellular collagen matrix.
4-6) Hypertension 
increases stiffness in the large arteries by inducing hy-
pertrophy and causing changes in the extracellular matrix 
(ECM).
7)8) The structural and functional manifestations 
of hypertensive left ventricle (LV) remodeling are asso-
ciated with significant changes in the ECM composi-
tion.
9) Matrix metalloproteinases (MMPs) are proteases 
that play an important role in the protein synthetic-lytic 
equilibrium of connective tissue.
10-12) Most MMPs are 
secreted into the extracellular milieu as inactive proteins. 
Their activity is modulated by tissue inhibitors of metal-
loproteinases (TIMPs).
12) 
There have been several studies exploring the relation-
ship among MMPs, their inhibitors, and LV structure 
and function in patients with hypertension.
13-18) MMPs 
are associated with cardiovascular disease and atheroscle-
rosis; in particular, MMP-2 and MMP-9 play important 
roles in the progression of atherosclerosis.
18) In a com-
munity-based study, atherosclerosis was found to be re-
lated to plasma MMP-9 levels not only in patients with 
systolic hypertension, but also in younger, apparently 
Received: January 22, 2009 
Accepted: March 24, 2009 
Correspondence: Young Mi Hong, MD, Department of Pediatrics, School of 
Medicine, Ewha  Womans University,  911-1 Mok-dong, Yangcheon-gu, 
Seoul 158-710, Korea 
Tel: 82-2-2650-2841, Fax: 82-2-2653-3718 
E-mail: hongym@chollian.net  
 
Yun Hee Lee, et al.·329 
healthy individuals.
19) 
MMP-3 may be particularly significant in arterial wall 
remodeling. This is due to its broad substrate spectrum, 
which includes most major constituents of the arterial 
wall: fibronectin, collagen types IV, V, IX, and X, gelastin, 
laminin, elastin, and proteoglycan proteins. In addition, 
MMP-3 activates other MMPs, such as MMP-1 and 
MMP-9.
20) 
However, the specific molecular and biochemical de-
terminants that contribute to this ECM remodeling proc-
ess in patients with hypertensive heart disease have not 
been fully elucidated. Most previous genetic studies have 
noted an association between MMPs and cardiovascular 
disease, though this has not been totally consistent. How-
ever, there has been no study addressing MMP-3 geno-
type in hypertensive adolescents.   
The purposes of this study were to compare the in-
cidence of the MMP-3 genotype in hypertensive and 
normotensive adolescents and to assess the effect of 
MMP-3 gene polymorphisms on carotid artery IMT and 
pulse wave velocity (PWV), which are markers of early 
atherosclerosis and vessel remodeling. 
 
Subjects and Methods 
 
Patients  
Forty-four hypertensive patients and 59 healthy ado-
lescents of similar age participated in this study (all pa-
tients greater than 16 but less than 17 years of age). Systolic 
blood pressures were greater than 140 mmHg or diastolic 
blood pressures were greater than 90 mmHg in all patients. 
All participants provided written informed consent. 
 
Anthropometric measurements 
All hypertensive students were referred to our pe-
diatric clinic. Their elevated blood pressures were ascer-
tained by averaging three blood pressure measurements 
made after 10 minutes of rest with an oscillometric mon-
itor. No patients had ever been diagnosed or treated for 
hypertension before. Height and body weight were meas-
ured, and body mass index (BMI) and obesity index 
(OI) were calculated from these figures. BMI was defin-
ed as weight (kg) divided by height squared (m
2). OI was 
calculated by the following equation using the standard 
weight as the value corresponding to the 50th percentile 
weight of Korean adolescents. 
Obesity index (%)=(weight measured-standard  
weight)/standard weight×100 
Obesity was defined as OI above 120 percent. Fat 
mass and fat distribution were measured by bioelectrical 
impedance analysis (Inbody 3.0, Biospace, Seoul, Korea). 
 
Intima-media thickness of the common carotid   
artery 
Carotid artery measurements were made using a real-
time B-mode ultrasound imager (iU22, intelligent Ul-
trasound System; Philips, Amsterdam, Netherlands) and 
a 12.5 MHz probe. For all subjects, the IMT and lumen 
diameter were measured in the same carotid arterial 
segment by the same radiologist. Patients were directed 
to lie down in a supine position for 30 minutes before 
measurements were made. The following equations were 
used to calculate carotid artery compliance and elasticity. 
Lumen cross-sectional area=πdD
2/4  
Wall cross-sectional area 
=π (dD/2+IMT)
2-π  (dD/2)
2 
Cross-sectional compliance 
={π   (sD
2-dD
2)}/4ΔP (mm
2·mmHg-1) 
Cross-sectional distensibility 
=(sD
2-dD
2)/(dD
2ΔP) (mmHg-1·10-2) 
IMT (mm) 
Systolic diameter (sD, mm) 
Diastolic diameter (dD, mm) 
ΔP: pulse pressure 
 
Pulse wave velocity and ankle brachial index   
Brachial-ankle PWV (baPWV) and ankle brachial in-
dex (ABI) were measured by VP-1000 (Colin Co., Ko-
maki, Japan). PWV, ABI (the ratio of systolic blood pres-
sure in the ankle to that in the brachial artery), blood 
pressures in both extremities, electrocardiography, and 
heart sounds were obtained simultaneously using volume 
plethysmographic technique. Cuffs were wrapped on 
both the arms and ankles, and electrocardiogram elec-
trodes were placed on the left sternal border. As the pulse 
wave contours in the four extremities were recorded, the 
cuffs inflated and deflated automatically. Cuffs were 
attached to the plethysmographic sensor, which deter-
mined the volume pulse form. Blood pressures were 
measured from the oscillometric pressure sensor. BaPWV 
was determined based on the pulse transit time and the 
distance between these two segments. The distance of 
each segment was calculated automatically, based on the 
height of each subject. All measurements were made 
during regular sinus rhythm. 
 
Serum aldosterone, renin, insulin, angiotensin con-
verting enzyme, homocysteine, vitamin B12, and 
folate levels 
Venous blood was drawn from all patients after over-
night fasting. Samples were kept at -70℃ for subsequent 
assay. Serum concentrations of aldosterone, renin, in-
sulin, vitamin B12, and folate were evaluated by radioim-
munoassay (RIA) with a COBRA-II Gamma Counter 
(Packard, Meriden Coonecticut, CA, USA). Angiotensin 
converting enzyme (ACE) was measured with enzyme 
linked immuno sorbent assay (ELISA) using COBAS 
MIRA (Roche, Switzerland). Homocysteine was measured 
by chemiluminoimmunoassay (CLIA) with an ADVIA 
Centaur HCY (Bayer, Tarrytown, New York, NY, USA).  
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Matrix metalloproteinase-1, matrix metalloprotei-
nase-2, matrix metalloproteinase-3, matrix metal-
loproteinase-9, tissue inhibitors of matrix metallo-
proteinases-1, and tissue inhibitors of matrix met-
alloproteinases-2 
Commercially available sandwich ELISA assays (Mo-
lecular Devices, Palmcity, FL, USA) were used to deter-
mine MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1, and 
TIMP-2 levels. We placed samples in a plate coated with 
specific total MMP-1 polyclonal antibodies and made 
specific antibodies. We then washed off the detached 
materials and added pro-MMP-1-specific enzymelinked 
polyclonal antibodies to each well. After substrate solu-
tion was added, total MMP-1 conjugates radiated. The 
absorbance was read spectrophotometrically with a mi-
crotiter plate reader. MMP-2, MMP-3, MMP-9, TIMP-
1, and TIMP-2 levels were measured using the same 
method. 
 
Determination of the matrix metalloproteinase-3 
genotype 
The sequences of polymerase chain reaction (PCR) 
primers were 5’-GATTACAGACATGGGTCACA-3’ 
(forward primer) and 5’-TTTCAATCAGGACAAGAC 
GAAGTTT-3’ (reverse primer). PCR was carried out in 
a total volume of 25 mL: 15 ng of genomic DNA, 5 
pmol of each primer, 200 mM each of dATP, dCTP, 
dGTP, and dTTP, 20 mM Tris-HCl (pH 8.4), 50 mM 
KCl, 5 mM MgCl2, and Taq polymerase (TaKAaRa). 
The solution was overlaid with 25 mL of liquid paraffin 
and incubated for 2 minutes at 95℃, 30 seconds at 
53℃, and 30 seconds at 72℃, with an additional 2 
minutes extension at 70℃  at the end of 35 cycles. The 
120 bp PCR product was cleaved with 10 U of Xnm I 
(New England Biolab, Bererly, MA, USA) and electro-
phoresed on 4% agarose; the allele produced one band 
of 120 bp (Fig. 1). 
 
Statistical analysis   
We performed all statistical analyses using the SPSS/ 
PC software package program (SPSS version 11.0). De-
scriptive statistics were presented as means and standard 
deviations.  
The correlations among continuous variables were 
determined using the Student t-test and one-way an-
alysis of variance (ANOVA). P less than 0.05 were consi-
dered statistically significant.   
 
Results 
 
Matrix metalloproteinase-3 genotype frequencies 
in hypertensive and normotensive adolescents 
MMP-3 genotype frequencies were 6A/6A 72.7% 
(n=32) and 5A/6A 27.3% (n=12) in hypertensive pa-
tients and 6A/6A 71.2% (n=42), 5A/6A 24.4% (n= 
15), and 5A/5A 3.4% (n=2) in control patients (Table 
1). The genotype frequencies did not significantly differ 
between hypertensive and normotensive adolescents. 
 
Blood pressure 
Blood pressure was significantly higher in the hyper-
tensive group compared to the control group, but nei-
ther systolic nor diastolic blood pressure showed a sta-
tistically significant difference according to genotype (Ta-
ble 2).  
 
 Anthropometric  data 
There were no significant differences in anthropo-
metric data such as height, weight, BMI, OI, fat mass, or 
fat distribution between patients with the 6A/6A geno-
type and those with the 5A/6A genotype (Table 3).  
 
Carotid intima media thickness and pulse wave   
velocity 
Carotid IMT and PWV were significantly higher in 
the hypertensive group than in the control group, but 
there was no significant difference between genotypes 
(Table 4). 
Table 1. MMP-3 genotype frequencies in the hypertensive and 
normotensive groups 
Genotype frequency   
No (%)  Group 
6A/6A  5A/6A  5A/5A 
Hypertensive group  32 (72.7)  12 (27.3)  0 (0)0. 
Normotensive group  42 (71.2)  15 (25.4)  2 (3.4) 
p>0.05 vs. control. MMP: matrix metalloproteinase 
   
Table 2. Comparison of BPs according to MMP-3 genotype in 
the hypertensive and normotensive groups 
Hypertensive group  Blood pressure 
(mmHg)  6A/6A  5A/6A 
Normotensive group
Systolic BP  153.8±11.0*  147.2±6.4* 115.9±15.9 
Diastolic BP  82.8±7.9*  084.9±4.3*  072.6±10.5 
*p<0.05 vs. control. BP: blood pressure, MMP: matrix metallo-
proteinase   
Fig. 1. MMP-3 gene expression in hypertensive adolescents and
controls. The allele produced one band of 120 bp size. Test1:
5A/5A mutant, Test2: 6A/6A normal, Control: saline. 
5A/6A         6A/6 A         Test1           Test2         Con trol   
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Serum aldosterone, renin, insulin, angiotensin con-
verting enzyme, vitamin B12, and folate levels 
Serum aldosterone (145.8±85.6 pg/mL vs. 80.3±50.1 
pg/mL) and homocysteine (13.2±5.8 μIU/mL vs. 10.2 
±2.5 μIU/mL) levels were significantly higher in the 
6A/6A genotype group than in the control group. 
Insulin levels were significantly higher in the hyper-
tensive group than in the control group. Vitamin B12 
levels were lower in the 6A/6A genotype group than 
they were in the control group (649.4±363.2 pg/mL vs. 
967.8±405.0 pg/mL). Folate levels were significantly 
lower in the hypertensive group than in the control group 
(Table 5). 
 
Serum matrix metalloproteinase and tissue inhibi-
tors of matrix metalloproteinases levels according 
to matrix metalloproteinase-3 genotype 
Serum MMP-3 levels were higher in the 6A/6A geno-
type group than in the 5A/6A genotype group, but not 
to a statistically significant degree. Serum MMP-9 levels 
were higher in the 5A/6A genotype group than in the 
control group (856.2±358.7 ng/mL vs. 603.4±292.7 
ng/mL). There were no significant differences in pro-
MMP-1, MMP-2, MMP-9, TIMP-1, or TIMP-2 levels 
according to MMP-3 genotype (Table 6). 
 
Discussion 
 
In our study, the MMP-3 genotype frequencies were 
6A/6A 72.7% and 5A/6A 27.3% in hypertensive ado-
lescents. The incidence was not significantly different 
between hypertensive and normotensive adolescents. 
Blood pressure, anthropometric data, carotid IMT, and 
baPWV were no different between the MMP-3 6A/6A 
and 5A/6A groups in hypertensive adolescents. Serum 
aldosterone, insulin, and homocysteine levels were higher 
in the 6A/6A group than in the control group, while 
vitamin B12 and folate levels were lower in the 6A/6A 
Table 5. Comparison of aldosterone, renin, insulin, angiotensin converting enzyme (ACE), homocysteine, vitamin B12, and folate levels ac-
cording to MMP-3 genotype in the hypertensive and normotensive groups 
Hypertensive group   
   
6A/6A  5A/6A   
Normotensive group 
Aldosterone (pg/mL)  145.8±85.6* 85.3±62.7 80.3±50.1 
Renin (ng/mL/hr)  4.3±3.3 3.7±1.8 2.6±3.4 
Insulin (μIU/mL)  021.4±14.8*  022.8±14.4* 7.9±2.9 
ACE (U/L)  46.1±19.8 63.9±52.4 45.4±18.5 
Homocysteine (μmol/L) 13.2±5.8* 10.6±2.50 10.2±2.50 
Vitamin B12 (pg/mL)  0649.4±363.2* 695.4±291.0 967.8±405.0 
Folate (ng/mL)  05.5±2.6*  06.4±2.8* 9.8±3.5 
*p<0.05 vs. control. MMP: matrix metalloproteinase, ACE: angiotensin converting enzyme       
Table 3. Anthropometric data according to MMP-3 genotype in the hypertensive and normotensive groups 
Hypertensive group   
Anthropometric data 
6A/6A  5A/6A   
Normotensive group 
Height (cm)  165.8±11.40 167.6±15.20 163.5±5.300 
Weight (kg)  069.2±18.1*  072.6±19.8* 55.4±4.70 
Body mass index (kg/m
2) 24.8±4.9* 25.3±3.9* 20.7±0.50 
Obesity index (%)  116.7±21.8* 117.8±13.8* 105.3±1.500 
Fat mass (kg)  18.8±9.2* 19.6±6.9* 14.2±4.60 
Fat distribution  00.86±0.07*  00.87±0.04* 0.78±0.01 
*p<0.05 vs. control. MMP: matrix metalloproteinase 
 
Table 4. Comparison of carotid IMT PWV and ABI according to MMP-3 genotype in the hypertensive and normotensive groups 
Hypertensive group   
Parameters   
6A/6A  5A/6A   
Normotensive group 
Carotid IMT (mm)  00.6±0.2*  00.6±0.1* 0.4±0.1 
RbaPWV (cm/sec)  1140.4±130.5* 1098.0±107.4* 925.7±251.4 
LbaPWV (cm/sec)  1172.7±123.6* 1114.3±91.3*0 928.4±233.1 
R-ABI 100.8±10.00 100.2±4.900 103.2±8.500 
L-ABI 102.0±8.800 104.2±6.200 102.5±7.800 
*p<0.05 vs. control. IMT: intima media thickness, MMP: matrix metalloproteinase, PWV: pulse wave velocity, ABI: ankle brachial index, 
RbaPWV: right brachial-ankle pulse wave velocity, LbaPWV: left brachial-ankle pulse wave velocity, R-ABI: right ankle-brachial index, L-ABI:
left ankle-brachial index 
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group. Serum MMP-3 levels were slightly higher in the 
6A/6A group than in the 5A/6A group, but not to a 
statistically significant degree. Serum MMP-9 levels were 
higher in the hypertensive group with the 5A/6A geno-
type than in the control group. However, there was no 
statistically significant difference between serum pro-
MMP-1, MMP-2, MMP-9, TIMP-1, and TIMP-2 levels. 
Most previous genetic studies have noted an associa-
tion between MMPs and cardiovascular disease, though 
this finding has not been completely consistent. Genetic 
variation in a number of MMP and TIMP genes has been 
implicated as a risk factor for atherosclerosis. However, 
the studies indicating these relationships have been gen-
erally small and have produced conflicting results.
21)  
Medley et al.
22) reported that the MMP-9 genotype 
influences large artery stiffness through effects on aortic 
gene and protein expression. MMP-9 genotype (C-1562T 
promoter polymorphism) T-allele carriers (C/T and T/ 
T) had stiffer large arteries and higher carotid pulse and 
systolic blood pressure than C/C homozygotes did. The 
higher expression of MMP-9 associated with the T allele 
may influence large arteries to become stiffer through 
vascular remodeling, which disrupts their mechanical in-
tegrity. This relationship may be due to increased degra-
dation of important elastic components of the ECM 
secondary to elevated MMP-9 gene expression and pro-
tein levels in the aorta.
22)  
An association was found between MMP-9 R279Q 
and internal carotid artery bulb IMT, but there was no 
linear trend between allele number and IMT and no 
association with common carotid artery or bulb IMT. 
Associations were noted between three polymorphisms 
(MMP-1 A-519G, MMP-3 5A/6A, and TIMP-3 T-1296C) 
and hypertension.
21) These findings provide little sup-
port for genetic variants of MMP as direct risk factors for 
IMT. However, the interaction between MMP variants 
and hypertension suggest that hypertensive carriers of 
these alleles may be at greater risk for increased IMT 
and future cardiovascular disease.
21) 
Altered MMP activity has been noted to be involved 
as a mechanism in early vascular remodeling secondary 
to hypertension. ECM is hypothesized to impede left 
ventricular diastolic filling, thus contributing to symp-
tomatic diastolic dysfunction in diabetic and hypertensive 
patients.
13) Several studies have been dedicated to deter-
mining the relationship among MMPs, their inhibitors, 
and LV structure and function.
14-17)  
Plasma MMPs play a role in the development of dia-
stolic dysfunction in hypertensive patients. Saglam et al.
14) 
found that plasma MMP-3 and MMP-9 levels were sig-
nificantly higher in patients with left ventricular hyper-
trophy (LVH). 
In an adult study, aortic and brachial PWV, as well as 
serum MMP-9, MMP-2, and elastase levels, were increas-
ed in older subjects with isolated systolic hypertension 
(ISH), compared with older controls.
19) In our study, 
MMP-9 levels were significantly higher in 5A/6A geno-
type patients compared with normal adolescents. Carotid 
IMT and PWV were significantly higher in hypertensive 
adolescents compared with normal controls. However, 
IMT and PWV were no different according to MMP-3 
genotype. Although the exact duration of hypertension 
was unknown in the patients in our study, it is probably 
too short to cause a significant difference in MMP levels 
according to genotype. IMT thickness appears to repre-
sent not only early atherosclerosis, but also adaptive re-
modeling, particularly in hypertension.
23) The effects of 
MMP genetic variants may not be pronounced enough 
to be detected by increases in IMT in normotensive sub-
jects at this early stage. However, as hypertension and 
the degree of vascular remodeling increase, the effect of 
these genetic variants will be manifested. 
In adult studies, MMP-9 levels have been found to 
correlate significantly with aortic and brachial PWV at an 
early time point.
19)22) Aortic stiffness is related to MMP-
9 and elastase levels, not only in ISH, but also in younger, 
apparently healthy individuals. This suggests that elastases 
including MMP-9 may be involved in arterial stiffening 
and the development of ISH.
19) Hypertensive patients 
showed higher levels of MMP-9 and TIMP-1. Spearman’s 
correlation analysis showed that serum levels of MMP-9 
and TIMP-1 were significantly and positively correlated 
with PWV in hypertensive patients. 
The MMP-9/TIMP-1 system may play an important 
role in the determination of arterial function, and these 
findings may have implications for the involvement of 
Table 6. Comparison of serum MMP and TIMP levels according to MMP-3 genotypes between hypertensive group and normotensive group
Hypertensive group   
   
6A/6A  5A/6A   
Normotensive group 
Pro-MMP-1 (ng/mL)  5.1±3.8 4.4±0.9 5.6±4.2 
MMP-2 (ng/mL)  320.8±77.50 334.7±46.30 356.2±61.20 
MMP-3 (ng/mL)  9.5±7.5 6.5±4.1 9.5±3.9 
MMP-9 (ng/mL)  731.2±341.9  0856.2±358.7* 603.4±292.7 
TIMP-1 (ng/mL)  163.4±33.80 163.8±20.20 160.7±32.00 
TIMP-2 (ng/mL)  82.9±13.0 80.6±7.70 90.3±20.6 
*p<0.05 vs. control. MMP: matrix metalloproteinase, TIMP: tissue inhibitor of metalloproteinase   
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the MMP-9/TIMP-1 system in the pathophysiology of 
cardiovascular disease.
24) 
The concomitant increases in both MMPs and TIMPs 
may indicate abnormal ECM turnover at the post-
translational level.
25) MMP-1 is likely to be relevant in 
the clinical setting. Ishikawa et al.
26) demonstrated that 
plasma MMP-1 levels significantly correlate with both 
the pulse pressure and the mean blood pressure in hy-
pertensive human patients with LVH. However, in our 
study, plasma pro-MMP-1 levels were not significantly 
different between hypertensive and nomotensive ado-
lescents. 
Early and late chronic pressure overload induces dis-
tinct changes in ECM phenotypes in particular MMPs 
and TIMPs. MMPs are predominantly attenuated dur-
ing the initial pressure overload, with increases in MMPs 
noted during the late phase of chronic pressure over-
load.
25) 
MMPs and TIMPs play an important role in collagen 
degradation.
25) However, whether the determinants of 
ECM composition, such as the balance between MMPs 
and TIMPs, are altered in hypertensive heart disease is 
unknown.
9) With respect to hypertensive heart disease, 
increased TIMPs and decreased MMPs favor decreased 
collagen degradation and increased collagen accumula-
tion. TIMPs tightly regulate the activities of MMPs.
18) Pa-
tients with hypertension, but normal LV structure and 
function, have been shown to have normal MMP/TIMP 
profiles.
9) Changes in MMP profiles that favor decreased 
ECM degradation have been associated with LVH and 
diastolic dysfunction, and increased TIMP-1 levels have 
been shown to predict the presence of congestive heart 
failure.
9) Although these findings should be confirmed 
in a larger prospective study, these data do suggest that 
changes in the MMP/TIMP balance may play an impor-
tant role in the structural, functional, and clinical mani-
festations of hypertensive heart disease.
9) It seems likely, 
therefore, that ongoing changes in MMPs and TIMPs 
will contribute to the phenotypic and structural changes 
present in hypertensive heart disease.
9) 
We noted no significant difference in serum MMP-3 
levels according to MMP-3 genotype in hypertensive ad-
olescents. Plasma levels do not necessarily reflect the net 
ECM proteolytic activity that occurs within the myocar-
dium. The myocardium is not the only source of MMPs 
and TIMPs in LVH patients. Therefore, plasma MMP 
and TIMP levels represent the sum of MMPs and TIMPs 
released from both cardiac and non-cardiac sources.   
Our study is limited in that it was small; we studied 
only 44 adolescents. It is also possible we failed to show 
the relationship between MMP-3 genotype and cardio-
vascular risk because our subjects were adolescents who 
had high blood pressure of short duration. Large sample 
size increases statistical power and reduces the problem 
of incomplete penetrance in individuals that may have 
subclinical hypertension, which will lead to clinical events 
in subsequent years. Carotid IMT has been successfully 
used to demonstrate robust, replicable associations with 
other cardiovascular candidate genes.
27) 
Our findings provide some support for genetic variants 
of MMP as direct risk factors for IMT , at least in the 
early stages of hypertension, through vessel remodeling 
and thickening.   
Further studies investigating the associations between 
MMP genotypes and symptomatic disease will be requir-
ed to determine if these variants play a role in hyper-
tension. IMT thickness appears to represent not only 
early atherosclerosis, but also adaptive remodeling, par-
ticularly to hypertension. Vascular remodeling is limited 
during early atherosclerotic changes, which IMT changes 
represent. As such, the effects of MMP genetic variants 
may not be pronounced enough to be detected by in-
creases in IMT in normotensive subjects at this early 
stage. However, as hypertension increases the degree of 
vascular remodeling, the effect of these genetic variants 
becomes manifest. 
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